Kras

New preclinical data indicate that the SIL204 treatment acts on three key mechanisms by which cancer tumors evade the immune system, strengthening the scientific basis for combination immunotherapy.

The Tel Aviv Sourasky Medical Center (Ichilov) and the Israeli biotech company Silenseed have launched a clinical trial for the drug SIL204. This innovative treatment targets the KRAS gene mutation, potentially marking a breakthrough in treating one of the deadliest forms of cancer.